Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Progress in Low-LET Heavy Particle Therapy: Intracranial and Paracranial Tumors and Uveal Melanomas

Mary Austin-Seymour, John E. Munzenrider, Michael Goitein, Richard Gentry, Evangelos Gragoudas, Andreas M. Koehler, Patricia McNulty, Estelle Osborne, David K. Ryugo, Joanna Seddon, Marcia Urie, Lynn Verhey and Herman D. Suit
Radiation Research Supplement
Vol. 8, Heavy Charged Particles in Research and Medicine. Proceedings of a Symposium Held at the Lawrence Berkeley Laboratory, University of California, Berkeley, California, May 1-3, 1985 (Nov., 1985), pp. S219-S226
DOI: 10.2307/3583531
Stable URL: http://www.jstor.org/stable/3583531
Page Count: 8
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Progress in Low-LET Heavy Particle Therapy: Intracranial and Paracranial Tumors and Uveal Melanomas
Preview not available

Abstract

The Harvard Cyclotron Laboratory in collaboration with the Department of Radiation Medicine of the Massachusetts General Hospital and the Retina Service of the Massachusetts Eye and Ear Infirmary provides low-LET heavy particle therapy with 160 MeV protons. The improved dose distribution of protons results from their physical characteristics. A total of 965 patients have been treated as of December 31, 1984. Dose is expressed in units of cobalt gray equivalent (CGE) which is the dose in Gy multiplied by the RBE (1.1) for modulated protons relative to 60 Co radiation. Sixty-seven patients with chordomas or low-grade chondrosarcomas of the base of skull or cervical spine have received proton treatment. Forty-three of these patients have been followed for at least 8 months with a median follow-up of 27 months. The median dose is 69 CGE. The 3-year actuarial local control rate is 89%. Seven patients with gliomas, eight with craniopharyngiomas, and six with meningiomas have also received proton radiation treatments. A total of 615 patients with uveal melanomas have received a median dose of 70 CGE in five fractions. Tumor regression has been seen in 94% with 66% having vision of 20/100 or better.

Page Thumbnails

  • Thumbnail: Page 
S219
    S219
  • Thumbnail: Page 
S220
    S220
  • Thumbnail: Page 
S221
    S221
  • Thumbnail: Page 
S222
    S222
  • Thumbnail: Page 
S223
    S223
  • Thumbnail: Page 
S224
    S224
  • Thumbnail: Page 
S225
    S225
  • Thumbnail: Page 
S226
    S226